340B Improves Access for Health Center Patients



June 2022

Since 2020, drug manufacturers' 340B contract pharmacy restrictions have greatly impacted health centers' ability to provide affordable medications to the patients that need them the most. NACHC conducted a survey to better understand the negative impact on patient outcomes due to the loss of 340B savings


92% of respondents utilize 340B savings to increase access for low-income and/or rural patients by maintaining or expanding services in underserved communities.



90% of respondents report that their 340B program has led to improved medication adherence, improved clinical outcomes, and improved access to care.

Health center patients with diabetes, heart disease, and behavioral health needs rely on drugs purchased through the 340B program more than other patient population. Without 340B, these patients would face much more severe health outcomes.

Health Centers' 340B Savings' Utilization and Implications for Access



of respondents
believe that over
HALF of their
patients would lose
access to needed
medication without
340B program
discounts.

Data comes from 302 individual health center respondents to NACHC's 340B survey, fielded from April 11 to May 13. For more information see accompanying report or contact Gracy Trinoskey-Rice at gtrinoskeyrice@nachc.org.